Lactiflorin, a monoterpene glycoside, has been used in the treatment of rheumatoid arthritis via inhibiting leukocyte recruitment and angiogenesis via, potentially, the VEGFR and PI3K-Akt signaling pathways, interleukin signaling, and platelet activation (57). The gene discussed is AKT1; the disease is rheumatoid arthritis.